

# Table of Contents

---

<b>About the Authors</b> .....	vii
<b>Table of Chapters</b> .....	ix
<b>Acknowledgments</b> .....	xix
<b>Introduction</b> .....	xxi

## **Chapter 1 Learning from Past and Current Pandemics**

§ 1:1	Drawing Lessons from Prior Events.....	1-1
§ 1:2	Classical Pandemics .....	1-2
§ 1:3	SARS .....	1-2
§ 1:4	Middle East Respiratory Syndrome.....	1-3
§ 1:5	Swine Flu .....	1-3
§ 1:6	Ebola .....	1-3
§ 1:7	Zika.....	1-4
§ 1:8	How Pandemic Experiences Have Taught Lessons .....	1-4
§ 1:9	Statistics for USA COVID-19 Cases.....	1-5
§ 1:10	Cases and Deaths Among Healthcare Personnel .....	1-5
§ 1:11	Jurisdictions Gathering Reportable Data in the United States.....	1-5
§ 1:12	Confirmed and Probable Counts .....	1-6
§ 1:13	Global Health Statistics.....	1-7

## **Chapter 2 Medical Workplace Challenges from COVID-19**

§ 2:1	COVID-19's Threat to Medical Workers .....	2-1
§ 2:2	How Is the Medical Hierarchy Organized for Coronavirus Responses?.....	2-2
§ 2:2.1	Healthcare Decision Making.....	2-2
§ 2:2.2	Hospitals .....	2-3
§ 2:2.3	Controls on Contract Healthcare Workers .....	2-4
§ 2:2.4	Credentialing .....	2-4
	[A] Government Licensure .....	2-5
	[B] Credentials Committee Gatekeepers .....	2-6
§ 2:3	Nursing Homes .....	2-7

§ 2:4	Telemedicine As a Tool for Evaluating Patients and Shielding the Provider .....	2-8
§ 2:4.1	Telehealth Waivers from the Centers for Medicare & Medicaid Services (CMS) .....	2-9
§ 2:4.2	HIPAA Flexibility During COVID-19.....	2-10
§ 2:5	Adequacy of Supplies of Healthcare Protective Equipment.....	2-10
§ 2:6	Nursing Homes and Long-Term Care: Shortages Can Be Fatal.....	2-11
§ 2:7	“Standard of Care” and Malpractice Claims in the COVID-19 Context.....	2-12
§ 2:8	Healthcare Worker Complaints About Working Conditions .....	2-14

**Chapter 3     Shutdowns, Layoffs and Furloughs**

§ 3:1	Types of Workplace Interruptions Related to COVID-19 Infections .....	3-1
§ 3:2	New Norms of Layoff and Disconnection of People.....	3-2
§ 3:3	Changing Worksites to Limit Potential Virus-Transmission Risks.....	3-3
§ 3:4	Employment Interruption Mandated by Government Orders .....	3-3
§ 3:5	Unionized Workers and Layoffs .....	3-4
§ 3:6	Emergency Powers.....	3-4
§ 3:7	Shutdown for Temporary Decontamination of Site.....	3-4
§ 3:8	Shutdown for Loss of Customer Access .....	3-5
§ 3:9	Shutdown for Government-Related Supply Chain Problems .....	3-5
§ 3:10	Agricultural Work Reductions Related to COVID-19 Disruption of the Food Supply Chains .....	3-6
§ 3:11	Unemployment Compensation Under 2020 CARES Legislation.....	3-6

**Chapter 4     Overview of Workplace Impacts of Responses to COVID-19**

§ 4:1	Overview of Employment Effects—Statistics of Impacts.....	4-1
§ 4:2	Worker Impacts .....	4-2
§ 4:3	Response Functions: Engineering and Administrative Controls—Separation and Redesign of Workstations and Workflow .....	4-4
§ 4:3.1	Workplace Risk Levels .....	4-5

## Table of Contents

§ 4:3.2	Elimination and Substitution.....	4-7
§ 4:3.3	Engineering Controls .....	4-7
§ 4:4	Administrative Controls.....	4-9
§ 4:5	Workplace Discipline for Not Observing Protective Steps .....	4-12
§ 4:6	The Impact of Vaccination on Workplace Responses.....	4-13

### **Chapter 5 COVID-19, Contracts and Frustration Defenses**

§ 5:1	How Will COVID-19 Challenges Impact Business Clients? .....	5-1
§ 5:2	How Does the “Force Majeure” Contract Clause Apply? .....	5-2
§ 5:3	Foreseeability.....	5-3
§ 5:4	Force Majeure Clauses in the Future .....	5-4
§ 5:5	Impossibility .....	5-5
§ 5:6	Impracticability .....	5-7
§ 5:7	Frustration of Purpose .....	5-8
§ 5:7.1	Examples of a Frustration Defense.....	5-8
§ 5:8	Statutory Law .....	5-9
§ 5:8.1	State Actions.....	5-9
§ 5:8.2	Federal Action.....	5-10

### **Chapter 6 Overview of Workplace Liability Claims**

§ 6:1	Overview of Employment Effects of the Virus Globally .....	6-1
§ 6:2	Worker Impacts .....	6-2
§ 6:3	Workplace Discipline for Not Observing Protective Operating Procedures .....	6-5
§ 6:4	Workplace Liability for Contracting COVID-19 .....	6-6
§ 6:5	Workplace Responses: Occupational Safety and Health Administration .....	6-7
§ 6:6	Resources for Workplace Compliance Programs.....	6-10
§ 6:7	Asymptomatic and Pre-Symptomatic Infection .....	6-11
§ 6:8	Core Principles of Case Investigation and Contact Tracing.....	6-12
§ 6:8.1	Effective Case Investigation and Contact Tracing Require Specialized Skills .....	6-13
§ 6:8.2	Key Considerations for Contact Tracing for COVID-19.....	6-13

**Chapter 7 Public-Sector Workplaces**

§ 7:1 Public Workers at Risk..... 7-1  
 § 7:2 Consider the Front-Line Roles of Public Employees..... 7-2  
 § 7:3 First Responder Exposure Concerns ..... 7-2  
 § 7:4 Staffing and Funding of Public Agencies After  
 COVID-19 ..... 7-3  
 § 7:5 Public-Sector Labor Relations ..... 7-3

**Chapter 8 Lockdown, Isolation, Quarantine and Travel Restrictions**

§ 8:1 Lockdown and Quarantine ..... 8-1  
 § 8:2 Historic Powers of Quarantine ..... 8-2  
 § 8:3 Quarantine..... 8-2  
 § 8:4 Isolation ..... 8-2  
 § 8:5 An Employee Who Is Positive for COVID-19  
 Should Isolate or Quarantine..... 8-2  
 § 8:6 Employees Without Symptoms but Who Have  
 Been Exposed to COVID-19 ..... 8-4  
 § 8:7 International Travel Controls ..... 8-4  
     § 8:7.1 Types of Notices..... 8-5  
     § 8:7.2 Requirements When Returning from  
     International Travel ..... 8-6

**Chapter 9 Understanding Testing Issues for COVID-19**

§ 9:1 Types of Tests ..... 9-1  
 § 9:2 The Potential Legal Issues from Testing ..... 9-2  
 § 9:3 Viral Tests ..... 9-2  
 § 9:4 Antibody Tests..... 9-4  
 § 9:5 Evaluating the Test Options—Sensitivity and  
 Specificity ..... 9-6  
 § 9:6 Roles of the FDA ..... 9-6  
 § 9:7 Risks of Fraud..... 9-7  
 § 9:8 Flaws in Results ..... 9-7  
 § 9:9 Tests for Management of COVID-19 Patients ..... 9-8  
 § 9:10 Environmental Testing ..... 9-8  
     § 9:10.1 Quantitative Methods for Evaluating  
     Environmental Hygiene ..... 9-8  
     § 9:10.2 Objective Methods for Evaluating Environmental  
     Hygiene ..... 9-9  
 § 9:11 Conclusion..... 9-11

**Chapter 10 Long-Term Health Issues**

§ 10:1 Uncertainty: Infection’s Likely Persistence and Recurrence..... 10-1

§ 10:2 Viral Effects Persistence Can Be Measured by Antibody Testing ..... 10-2

§ 10:3 Lung Effect Consequences for Surviving Patients..... 10-2

§ 10:4 Susceptibility to Infections After Recovery from Acute Incident..... 10-2

§ 10:5 Employee Refusal to Reenter Workplace ..... 10-3

§ 10:6 Work-Related Post-COVID Disability Payments..... 10-3

**Chapter 11 Prevention and Treatment: Vaccines and Drugs**

§ 11:1 What Is a Vaccine? ..... 11-1

§ 11:2 How Will the Vaccine Stop COVID-19? ..... 11-2

§ 11:3 How Is a Vaccine (or Drug) Developed? ..... 11-3

§ 11:4 How Is Marketing of a Vaccine Approved?..... 11-4

§ 11:5 What Could Go Wrong? ..... 11-5

§ 11:6 Beyond Vaccines ..... 11-5

§ 11:7 Drug Treatment for COVID-19..... 11-5

§ 11:8 NIH Recommendations for Treatment—Standard of Care? ..... 11-6

Table 11-1 Recommendation Rating Scheme ..... 11-7

§ 11:9 Presentation of Symptoms for Treatment ..... 11-8

§ 11:10 Incubation Periods..... 11-8

§ 11:11 Signs and Symptoms ..... 11-9

    § 11:11.1 Asymptomatic and Pre-Symptomatic Infection... 11-11

    § 11:11.2 Asymptomatic and Pre-Symptomatic Transmission ..... 11-11

**Chapter 12 Employer Healthcare Insurance Eligibility Issues**

§ 12:1 How Much Will Hospital Treatment of COVID-19 Patients Cost?..... 12-1

§ 12:2 Employer Insurance Programs Impacted by Coronavirus ..... 12-3

§ 12:3 Cost Burdens on Patients ..... 12-4

§ 12:4 Causes of Infection Influencing Coverage..... 12-6

§ 12:5 Contractual Coverages ..... 12-9

§ 12:6 Second and Subsequent Infection Costs ..... 12-10

§ 12:7 Litigating Denials of Coverage for Harm from COVID-19 ..... 12-11

§ 12:8 Failure of Diagnostic Efforts to Detect the Virus ..... 12-12

**Chapter 13 Death Benefit Issues**

§ 13:1 Life Insurance Payment As Employee Benefit ..... 13-1  
 § 13:2 Corporate Employer COVID-19 Liability ..... 13-1  
 § 13:3 Public-Employer Compensation ..... 13-2

**Chapter 14 Business Liability Risks from On-Site Infections**

§ 14:1 Business Liability from Exposures to SARS-CoV-2 ..... 14-1  
 § 14:2 The “Invitee” and “Licensee” Status..... 14-2  
 § 14:3 Workers’ Compensation Exclusivity ..... 14-3  
 § 14:4 Statutory Presumptions..... 14-4  
 § 14:5 Workers’ Compensation Change Alternatives ..... 14-6  
 § 14:6 OSHA “Recordable Illness” Criteria ..... 14-7  
 § 14:7 OSHA and State Workers’ Compensation Decisions ..... 14-10  
 § 14:8 Emergency OSHA COVID-19 Standard ..... 14-11  
 § 14:9 Use of Preventive Chemicals ..... 14-12  
 § 14:10 Smaller Employers (Less Than Ten Employees) ..... 14-13  
 § 14:11 Claims by Federal Employees ..... 14-13

**Chapter 15 Employment Discrimination Issues**

§ 15:1 EEOC Guidance and State Workplace  
 Discrimination Standards..... 15-1  
 § 15:2 Relevant Americans with Disabilities Act (ADA)  
 Requirements During a Pandemic ..... 15-3  
 § 15:3 Disability-Related Inquiries and Medical Examinations.... 15-4  
 § 15:4 Direct Threat and COVID-19 Pandemic ..... 15-5  
 § 15:5 Reasonable Accommodation..... 15-7  
 § 15:6 Responses During a Pandemic..... 15-7  
 § 15:7 Remedies for Disability Discrimination Issues in  
 Federal and State Law ..... 15-9  
 § 15:8 “Disability” Definition Is Changing ..... 15-9  
 § 15:9 Federal SSI Norms of “Disability” ..... 15-10  
 § 15:10 Permanent Disability Concerns for COVID-19  
 Survivors ..... 15-11

**Chapter 16 Regulatory Oversight of Tools Used to Fight COVID-19**

§ 16:1 Overview of Regulatory Oversight..... 16-1  
 § 16:2 Emergency Use Authorization (EUA) Clearance ..... 16-1  
 § 16:3 Regulation of Personal Protective Equipment (PPE) ..... 16-4  
 § 16:4 Regulation of Patient Devices and Ventilators ..... 16-7

*Table of Contents*

§ 16:5 Regulation of Sterilants, Disinfectants and Sanitizers..... 16-11  
§ 16:6 Regulation of Medications ..... 16-14  
§ 16:7 Regulation of Diagnostic Devices ..... 16-14

**Chapter 17 Advising About Tort Immunity in COVID-19 Claims**

§ 17:1 What Is Immunity? ..... 17-1  
§ 17:2 State Workers' Compensation ..... 17-2  
§ 17:3 State Medical Immunity Laws..... 17-2  
§ 17:4 Federal Immunity Laws ..... 17-2  
§ 17:5 The Immunity That Shields COVID-Use Products..... 17-3

**Chapter 18 Responding to Future Client Needs**

§ 18:1 Finding Success As an Advocate During the Pandemic .... 18-1  
§ 18:2 Counseling the Healthcare Providers..... 18-2  
§ 18:3 Documentation Is Essential but Difficult ..... 18-2  
§ 18:4 Defending the Products ..... 18-3  
§ 18:5 Using the Human Resources Office Files..... 18-3  
§ 18:6 Your Client's Readiness for Future Pandemics ..... 18-4

**Appendix A The CARES Act—Selected Provisions** ..... App. A-1

**Appendix B CDC Guidance for Manufacturing Workers and Employers**..... App. B-1

**Appendix C OSHA Guidance on Preparing Workplaces for COVID-19** ..... App. C-1

**Appendix D Equal Employment Opportunity Commission: What You Should Know About COVID-19 and the ADA, the Rehabilitation Act, and Other EEO Laws**..... App. D-1

**Appendix E HHS Emergency Declaration** ..... App. E-1

**Appendix F FDA Emergency Use Authorization Guidance**..... App. F-1

**Appendix G EPA Guidance on Safe and Effective Disinfectant Use** ..... App. G-1

**Appendix H HHS Guidance on Interpreting COVID-19 Test Results**..... App. H-1

**Index**..... I-1

